{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:09:30Z","timestamp":1793830170567,"version":"4.6.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>The oral PI3K-\u03b4,\u03b3 inhibitor duvelisib demonstrated clinical activity and a favorable safety profile in patients with CTCL and PTCL. Duvelisib induced cell-autonomous killing of TCL lines and reprogrammed PTCL-associated macrophages in vivo.<\/jats:p>","DOI":"10.1182\/blood-2017-08-802470","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T13:57:54Z","timestamp":1513087074000},"page":"888-898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":285,"title":["Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma"],"prefix":"10.1182","volume":"131","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-5685","authenticated-orcid":false,"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-023X","authenticated-orcid":false,"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Perez","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-3335","authenticated-orcid":false,"given":"Patricia","family":"Myskowski","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Officer","sequence":"additional","affiliation":[{"name":"Broad Institute of Harvard and MIT, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-1210","authenticated-orcid":false,"given":"Jacob D.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Broad Institute of Harvard and MIT, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara N.","family":"Morrow","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Allen","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Douglas","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Stern","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kelly","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kelly","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-9070","authenticated-orcid":false,"given":"Jon C.","family":"Aster","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weaver","sequence":"additional","affiliation":[{"name":"Verastem Pharmaceuticals, Needham, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale University Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Broad Institute of Harvard and MIT, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111812554357100_B1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111812554357100_B2","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2019111812554357100_B3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111812554357100_B4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111812554357100_B5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111812554357100_B6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111812554357100_B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2019111812554357100_B8","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111812554357100_B9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2019111812554357100_B10","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111812554357100_B11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111812554357100_B12","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10094","key":"2019111812554357100_B13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"2019111812554357100_B14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med"},{"issue":"5583","key":"2019111812554357100_B15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"5","key":"2019111812554357100_B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2019111812554357100_B17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell Signal"},{"issue":"2","key":"2019111812554357100_B18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"2019111812554357100_B19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"2019111812554357100_B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"issue":"7629","key":"2019111812554357100_B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"4","key":"2019111812554357100_B22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"issue":"7629","key":"2019111812554357100_B23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"issue":"4","key":"2019111812554357100_B24","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","article-title":"Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing","volume":"173","author":"Reif","year":"2004","journal-title":"J Immunol"},{"issue":"11","key":"2019111812554357100_B25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"key":"2019111812554357100_B26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8559","article-title":"High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K-)\u03b4,\u03b3 inhibitor, duvelisib [abstract]","volume-title":"J Clin Oncol","author":"Faia","year":"2015"},{"issue":"13","key":"2019111812554357100_B27","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111812554357100_B28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V124.21.328.328","article-title":"Duvelisib (IPI-145) inhibits malignant B-cell proliferation and disrupts signaling from the tumor microenvironment through mechanisms that are dependent on PI3K-delta and PI3K-gamma [abstract]","volume":"124","author":"Peluso","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111812554357100_B29","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2019111812554357100_B30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"2019111812554357100_B31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019111812554357100_B32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111812554357100_B33","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111812554357100_B34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J Exp Med"},{"issue":"21","key":"2019111812554357100_B35","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111812554357100_B36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1074\/mcp.M116.058354","article-title":"Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes","volume":"15","author":"Abelin","year":"2016","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"2019111812554357100_B37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111812554357100_B38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"issue":"2","key":"2019111812554357100_B39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V83.2.452.452","article-title":"Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma","volume":"83","author":"Chang","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2019111812554357100_B40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc3944","article-title":"Examining the utility of patient-derived xenograft mouse models","volume":"15","author":"Aparicio","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111812554357100_B41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111812554357100_B42","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","article-title":"Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides","volume":"39","author":"Louie","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2019111812554357100_B43","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"2019111812554357100_B44","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/8\/888\/1466752\/blood802470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/8\/888\/1466752\/blood802470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:49:50Z","timestamp":1660106990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/8\/888\/104427\/Activity-of-the-PI3K%CE%B4%CE%B3-inhibitor-duvelisib-in-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-802470","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732292396.793577570","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}